FDA approves moxidectin to treat river blindness

The FDA has approved moxidectin 8 mg oral for the treatment of river blindness in patients older than 12 years, according to a press release.
River blindness, caused by the parasitic worm Onchocerca volvulus, is spread by black flies that breed in the rivers of sub-Saharan Africa, Yemen, and South and Central America. Larvae invade skin and eyes, where they can cause permanent blindness, itching and disfiguring skin conditions, the release said.
Developed by the not-for-profit biopharmaceutical company Medicines Development for Global Health (MDGH) and the World Health Organization Special

Full Story →